Breast Cancer Suite
The CE-IVD marked AI model supports the detection of invasive carcinoma and scoring of Ki67 positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- Saved time, especially in the whole slide image scoring (up to 55% faster)
The CE-IVD marked AI model supports the detection of invasive carcinoma and scoring of ER positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- The AI-Assisted diagnosis and ER scoring saved time, especially in the whole slide image scoring (up to 37% faster)
The CE-IVD marked AI model supports the detection of invasive carcinoma and scoring of PR positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- The AI-Assisted diagnosis and PR scoring produced reductions in average time spent per slide in the WSI analyses (12% faster)
Breast Cancer Suite
Aiforia® Breast Cancer Ki67
The CE-IVD marked AI model supports the detection of invasive carcinoma and scoring of Ki67 positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- Saved time, especially in the whole slide image scoring (up to 55% faster)
Aiforia® Breast Cancer ER
The CE-IVD marked AI model supports the detection of invasive carcinoma and scoring of ER positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- The AI-Assisted diagnosis and ER scoring saved time, especially in the whole slide image scoring (up to 37% faster)
Aiforia® Breast Cancer PR
The CE-IVD marked AI model supports the detection of invasive carcinoma and scoring of PR positive and negative tumor cells from whole slide images (WSI) or from selected image areas of cancerous breast tissue.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- The AI-Assisted diagnosis and PR scoring produced reductions in average time spent per slide in the WSI analyses (12% faster)
Lung Cancer Suite
The CE-IVD marked AI model supports the detection of invasive carcinoma areas in patient samples and the scoring of PD-L1 negative and positive tumor cells in non-small cell lung (NSCLC) cancer cases.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- The AI-Assisted Dx and PD-L1 scoring saved time (~22% faster)
Lung Cancer Suite
Aiforia® Lung Cancer PD-L1
The CE-IVD marked AI model supports the detection of invasive carcinoma areas in patient samples and the scoring of PD-L1 negative and positive tumor cells in non-small cell lung (NSCLC) cancer cases.
Clinical Validation
- Showed excellent correlation with visual diagnosis
- Improved diagnostic concordance by increasing pathologist agreement
- The AI-Assisted Dx and PD-L1 scoring saved time (~22% faster)
Prostate Cancer Suite
The CE-IVD marked AI model supports the detection of adenocarcinoma and assists Gleason grade grouping from whole slide images (WSI).
Clinical Validation
- Showed excellent correlation with visual diagnosis
- The AI-Assisted Gleason scoring produced significant time savings by reducing the time spent per slide by 34%
Prostate Cancer Suite
Aiforia® Prostate Gleason Grade Groups
The CE-IVD marked AI model supports the detection of adenocarcinoma and assists Gleason grade grouping from whole slide images (WSI).
Clinical Validation
- Showed excellent correlation with visual diagnosis
- The AI-Assisted Gleason scoring produced significant time savings by reducing the time spent per slide by 34%
Why use AI?
Increased efficiency
Diagnose more patients in less time by unbinding yourself from time-consuming, manual tasks.
Advanced precision
Improve diagnostic accuracy and be confident in your decision-making.
Improved consistency
Reduce variability to standardize your sample review and ensure democratized patient care.
What makes Aiforia unique?
Future-proof
Together with our customers, we continue to develop new groundbreaking AI models, with thousands of models already developed for research use. We’re committed to providing cutting-edge deep learning AI models designed to meet the evolving needs of our customers. As clinical diagnostics become increasingly complex, our advanced software will ensure you stay at the forefront of technology.
Transparency
Aiforia makes a commitment to keeping our AI algorithms transparent and understandable. You remain in control, see how analyses are conducted, and participate in the training process. AI models serve as first-read support while the expert verifies the results. We offer our customers with fully quantifiable data and results that can easily be adjusted.
Ease of use
The Aiforia software requires no data scientists or coding expertise. Our team of experts integrates the solutions into existing IT infrastructures. We acknowledge that every lab is different, so we optimize each model for each lab’s individual needs and monitor their performance to deliver continuous improvement. Aiforia’s software allows customers to confidently scale up their operations while paying only for what they need.
Security
We take data privacy and security very seriously. We hold several globally relevant quality and security certifications, so our customers can be sure their sample and patient data is safe.* Customers determine what information is stored in the cloud and can opt for a private version.
*Our image analysis solutions are developed and maintained securely per ISO 27001:2013 and SOC 2 Type II security standards, and ISO 13485:2016 quality standards.
ON-DEMAND WEBINAR
Aiforia’s CE-IVD marked clinical AI models for Ki67 and PD-L1
Watch this recording for an intro and demo from pathologists Dr. Laury and Dr. Sjöblom on the Aiforia® Clinical AI Model for Lung Cancer; PD-L1 and Aiforia® Clinical AI Model for Breast Cancer; Ki67.
Why the cloud?
A cloud-based platform allows any laboratory with infinitely scalable digital pathology deployment.
Our services
Integration Services
Integration can be straightforward. Aiforia solutions can be integrated with any existing laboratory infrastructure to enjoy the full benefits of a digitized workflow.
Cloud Hosting Services
Choose to host on our secure shared or private cloud environment. You can also opt to host on your own cloud provider (preferred partners include MS Azure and GCP).
Custom AI Services
AI models developed by scientists, for scientists. With Custom AI Services, Aiforia's scientists build AI models for your specific needs.
AI for clinical diagnostics
INTERVIEW
Benefits of AI and digital pathology to the clinical lab
We interviewed two pathologists from different hospitals, Dr. Kevin Sandeman and Dr. Tuomas Mirtti, on their thoughts about the impact and benefits of AI and digital pathology in clinical diagnostics.
BLOG POST
5 reasons to use AI in clinical diagnostics
What additional benefit does AI bring to the digitized pathology workflow in clinical diagnostics? Read our article to find out.
NEWS
Aiforia obtains CE-IVD mark for AI-supported breast cancer diagnostics
Read our article to find out why the Aiforia Ki67 AI Model is a first-of-its kind diagnostic tool for pathologists to harness the full potential of their own expertise.
NEWS
Epredia and Aiforia announce partnership
We are thrilled to announce our partnership with Epredia, a global leader in precision cancer diagnostics, for the global distribution of our AI-powered pathology software!
NEWS
Aiforia and X-ZELL partner to scale up novel AI-powered method for early cancer detection
Aiforia partners with med-tech company X-ZELL to combine deep learning software with rare cell detection tech to build a novel, AI-powered method for early cancer detection.
Seeing is believing
Get a virtual demo from one of our experts
During the personalized walkthrough of Aiforia's software and solutions find out how to enhance your image analysis work in:
- Diagnostic pathology
- Preclinical studies
- Medical research
- Remote education